2012 NIDA Translational Avant-Garde Award for Medication Development for the Treatment of Substance Use Disorders (DP1)

The summary for the 2012 NIDA Translational Avant-Garde Award for Medication Development for the Treatment of Substance Use Disorders (DP1) Federal Grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the government agency that is offering this grant.
Federal Grant Title: 2012 NIDA Translational Avant-Garde Award for Medication Development for the Treatment of Substance Use Disorders (DP1)
Federal Agency Name: National Institutes of Health
Grant Categories: Education Health
Type of Opportunity: Discretionary
Funding Opportunity Number: RFA-DA-12-010
Type of Funding: Grant
CFDA Numbers: 93.279
CFDA Descriptions: Drug Abuse and Addiction Research Programs
Current Application Deadline: Feb 21, 2012
Original Application Deadline: Feb 21, 2012
Posted Date: Jul 29, 2011
Creation Date: Jul 29, 2011
Archive Date: Mar 23, 2012
Total Program Funding: $3,000,000
Maximum Federal Grant Award: $1,000,000
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching: No
Grant Description
The NIDA Translational Avant-Garde Award is designed to support dedicated and talented basic and/or clinical researchers with the vision, drive and expertise necessary to translate research discoveries into medications for the treatment of Substance-Use Disorders (SUDs). Through this FOA, the National Institute on Drug Abuse (NIDA) is committed to advancing the development of safe and efficacious medications for the treatment of SUDs stemming from tobacco, cannabis, cocaine, methamphetamine, heroin, or prescription opiate use. Medications can be either small molecules or biologics. Biologics include vaccines and recombinant therapeutic proteins created by biological processes. Applications may focus on the treatment of substance use (i.e., abuse or dependence) disorders and specific clinical manifestations of these disorders such as withdrawal, craving, or relapse.Applications that focus on the development of new formulations of marketed medications that are available for other indications, or new combinations of existing medications that hold promise for the treatment of SUDs, are also within the scope of this RFA.
Applicants Eligible for this Grant
State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.
Link to Full Grant Announcement
http://grants.nih.gov/grants/guide/rfa-files/rfa-da-12-010.html
Grant Announcement Contact
NIH OER WebmasterFBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [FBOWebmaster@OD.NIH.GOV]
Similar Government Grants
Avenir Award Program for Research on Substance Abuse and HIV/AIDS (DP2)
Avenir Award Program for Genetics or Epigenetics of Substance Abuse (DP2)
Effects of Cannabis Use and Cannabinoids on the Developing Brain (R01)
Effects of Cannabis Use and Cannabinoids on the Developing Brain (R21)
Effects of Cannabis Use and Cannabinoids on the Developing Brain (R03)
NIDA Phase II Small Business Innovation Research (SBIR [R44]) Competing Renewal Awards
Drug Abuse Aspects of Hiv/Aids and Other Infections
Epidemiology of Drug Abuse
More Grants from the National Institutes of Health
Brain Somatic Mosaicism and its Role in Psychiatric Disorders (U01)
Brain Somatic Mosaicism and its Role in Psychiatric Disorders (Collaborative U01)
Dimensional Approaches to Research Classification in Psychiatric Disorders (R01)
Novel Tools for Investigating Brain-derived GPCRs in Mental Health Research (R43/R44)
Novel Tools for Investigating Brain-derived GPCRs in Mental Health Research (R41/R42)

FederalGrants.com is not endorsed by, or affiliated with, any government agency. Copyright ©2014 FederalGrants.com